Shenzhen Hepalink Pharmaceutical Co Ltd (002399.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE100000P02

Price
9.47 CNY
Market cap
13.90 bn CNY
P/E (2025)
39.76
P/S (2025)
2.54
Dividend yield
1.53 %
Net margin
6.38 %
Return on equity (ROE)
2.90 %
Return on assets (ROA)
2.10 %

Shenzhen Hepalink Pharmaceutical Co Ltd financials

Fiscal year20242025
Revenue5.26 bn CNY5.48 bn CNY
Gross profit1.74 bn CNY1.74 bn CNY
Operating income507.12 m CNY635.97 m CNY
EBIT879.72 m CNY473.68 m CNY
Net income646.74 m CNY349.49 m CNY
Diluted EPS – continuing operations0.44 CNY0.24 CNY

Full history since 2006, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Shenzhen Hepalink Pharmaceutical Co Ltd

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs. It also provides molecule biologics CDMO services, which include research and development, manufacturing, quality management, and program management services, as well as technical support services. In addition, the company develops apabetalone (RVX-208), a BET bromodomain protein inhibitor in Phase 3 trial to reduce major adverse cardiovascular events, as well as in Phase 2 trial for diabetic nephropathy and fatty disease; oregovomab, a monoclonal antibody in Phase 3 trial for ovarian cancer, as well as in Phase 2 for pancreatic cancer; tosatoxumab (AR-301), a fully human IgG1 monoclonal antibody in Phase 3 trial for ventilator-associated pneumonia; and H1710, a heparanase inhibitor preparation for solid tumors. Further, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. The company was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 06.11.2026. Details in the risk notice.